{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"Number of patients reporting at least one adverse event at least possibly related to treatment.","groups":[{"description":"Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.\n\n\\>\n\n\\> carmustine: Given IV\n\n\\>\n\n\\> thiotepa: Given IV\n\n\\>\n\n\\> stem cell transplant\n\n\\>\n\n\\> G-CSF","id":"OG000","title":"Arm I"},{"description":"Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.\n\n\\>\n\n\\> cytarabine: Given IV\n\n\\>\n\n\\> etoposide: Given IV\n\n\\>\n\n\\> G-CSF","id":"OG001","title":"Arm II"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"7 years","title":"Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0","type":"SECONDARY","unitOfMeasure":"Participants"}